

## CURRICULUM VITAE

**LUMINARI Stefano**, born in Bologna Nov, 3rd, 1971: married, two children.

email; [sluminari@unimore.it](mailto:sluminari@unimore.it)

ORCID id. 0000-0001-8446-2285

Scopus Id. 6603622491

Researcher id. 5916-2014

### Current position:

**Full PROFESSOR MEDICAL ONCOLOGY, University of Modena and Reggio Emilia.**

**Head of the unit for “Clinical research in oncohematology” at the Hematology Division, AUSL IRCCS Reggio Emilia**

### Other positions:

- Chair of the “indolent lymphoma” committee of the Fondazione Italiana Linfomi (FIL) (2019 – 2023)
- Legal representative for the European Community of the International Extranodal Lymphoma Study Group (IELSG)(2020 - ongoing)
- Associate Editor of Italian edition of “Blood” (2019 - ongoing)
- Associate editor of the British Journal of Hematology (2022 – Ongoing)
- Board of directors member of the Fondazione Italiana Linfomi (2023 – ongoing)
- Board of directors member of the International extranodal lymphoma study group (2024- ongoing)

**Summary of research and clinical interests.** Dr. Luminari’s activity is highly focused on clinical research in malignant lymphomas. In particular he is an expert in biomarker and prognostic studies, in phase II and III clinical trials, and in population based studies. His research topics include indolent lymphomas, in particular Follicular Lymphomas, Hodgkin lymphomas, aggressive lymphomas (mainly elderly patients) and the use of FDG-PET in lymphomas. His most recent research activity is focused on the integration of radiomic and genomic data for the discovery of novel prognostic factors in lymphomas. He is current chair of the the international observational “T-Cell Project” study which has collected more than 1000 patients from 5 continents and is PI of the IELSG50 phase II trial conducted in China for the treatment of ENKTCL. He is author or coauthor of 216 publications listed on ISI and/or Scopus and printed on international peer reviewed journals and of three chapter books. His H-index (Scopus) is 48 as of Jun, 2024.

### **5 most recent publications related to the project**

1. Arcaini L, Bommier C, Alderuccio JP..., Luminari S. Marginal zone lymphoma international prognostic index: a unifying prognostic index for marginal zone lymphomas requiring systemic treatment. *EClinicalMedicine*. 2024 Apr 11; PMID: 38633575 Free PMC article. **LAST AUTHOR**
2. Luminari S, Manni M, Galimberti S, et al. Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study. *J Clin Oncol*. 2022 Mar 1; PMID: 34709880 **FIRST AUTHOR**
3. Gini G, Tani M, Tucci A, ... Luminari S. Lenalidomide plus rituximab for the initial treatment of frail older patients with DLBCL: the FIL\_ReRi phase 2 study. *Blood*. 2023 Oct 26; PMID: 37418685 **LAST AUTHOR**
4. Durmo R, Donati B, Rebaud L, ..., Luminari S. Prognostic value of lesion dissemination in doxorubicin, bleomycin, vinblastine, and dacarbazine-treated, interimPET-negative classical Hodgkin Lymphoma patients: A radio-genomic study. *Hematol Oncol*. 2022 Oct; PMID: 35606338 **5. LAST AUTHOR**
5. Foss FM, Hitz F, Radford J, ..., Luminari S, Federico M. The SALENTO prognostic model for limited-stage peripheral T-cell lymphoma from the International T-Cell Project Network. *Blood Adv*. 2023 Sep 12; PMID: 37163360 **SECOND LAST AUTHOR**

Modena 28/6/2024

